Arcutis Biotherapeutics Business Summary

Arcutis Biotherapeutics, Inc. (ARQT) is a commercial-stage biopharmaceutical leader in immuno-dermatology, generating revenue through net product sales of its flagship ZORYVE (roflumilast) franchise. The company’s revenue model transitioned to a fully independent commercial structure in January 2026 after terminating its co-promotion agreement with Kowa Pharmaceuticals. Arcutis operates across three primary segments—plaque psoriasis, seborrheic dermatitis, and atopic dermatitis—leveraging its proprietary phosphodiesterase-4 (PDE4) inhibitor platform in both cream and foam formulations. For fiscal year 2026, the company projected net product sales between $455 million and $470 million, driven by a 20% expansion of its specialized sales force to accelerate conversion from topical corticosteroids. Arcutis competes directly with Dermavant Sciences (VTAMA), Incyte (OPZELURA), and Amgen (Otezla). Within this landscape, Arcutis maintains the leading share among non-steroidal topicals, positioning itself as a primary challenger to the multi-billion dollar steroid market with a long-term target of 15-20% market penetration. Founded in 2016 by industry veterans Bhaskar Chaudhuri, PhD, David Socks, and Aditya Kohli, PhD, Arcutis is led by President and CEO Frank Watanabe, whose background includes executive roles at Kythera Biopharmaceuticals and Amgen. The current leadership team features CFO Latha Vairavan (promoted May 2025), Chief Technical Officer Bethany Dudek, and Chief Medical Officer Patrick Burnett, MD, PhD, alongside Chief Commercial Officer Todd Edwards and Chief Digital and Technology Officer Raj Madan. Following the retirement of co-founder Bhaskar Chaudhuri from the board in late 2025, the company appointed Amit Munshi to its Board of Directors, which is chaired by Keith Leonard. Arcutis has historically secured significant backing from premier life science investors, including HBM Partners, Frazier Healthcare Partners, Bain Capital Life Sciences, and OrbiMed, supporting its evolution from a clinical-stage startup to a multi-billion dollar commercial entity.